Objective: We designed a prospective, randomized, controlled, double-blind study to evaluate the efficacy of hippocampal deep brain stimulation (Hip-DBS) in patients with refractory temporary lobe epilepsy (TLE). Methods: Sixteen adult patients with refractory TLE were studied. Patient's workup included medical history, interictal and ictal electroencephalography (EEG), and highresolution 1.5T magnetic resonance imaging (MRI). Patients were randomized on a 1:1 proportion to an active (stimulation on) or to a control (no stimulation) arm. After implantation, patients were allowed to recover for 1 month, which was followed by a 1-month titration (or sham) period. The 6-month blinded phase started immediately afterward. A postoperative MRI confirmed the electrode's position in all patients. All patients received bipolar continuous stimulation. Stimulus duration was 300 ls and frequency was 130 Hz; final intensity was 2 V. Patients were considered responders when they had at least 50% seizure frequency reduction. Results: All patients had focal impaired awareness seizures (FIAS, complex partial seizures), and 87% had focal aware seizures (FAS, simple partial seizures). Mean preoperative seizure frequency was 12.5 AE 9.4 (mean AE standard deviation) per month. MRI findings were normal in two patients, disclosed bilateral mesial temporal sclerosis (MTS) in three, left MTS in five, and right MTS in six patients. An insertional effect could be noted in both control and active patients. In the active group (n = 8), four patients became seizure-free; seven of eight were considered responders and one was a nonresponder. There was a significant difference regarding FIAS frequency between the two groups from the first month of full stimulation (p < 0.001) until the end of the blinded phase (p < 0.001). This was also true for FAS, except for the third month of the blinded phase. Significance: Hip-DBS was effective in significantly reducing seizure frequency in patients with refractory TLE in the active group, as compared to the control group. Fifty-percent of the patients in the active group became seizure-free. The present study is the larger prospective, controlled, double-blind study to evaluate the effects of Hip-DBS published to date.
Neuromodulatory techniques have been used with increasing frequency to treat refractory epilepsy. Deep brain stimulation has proved to be effective in treating this patient population in two prospective double-blind, controlled studies: the Stimulation of the Anterior Nucleus of the Thalamus cin Epilepsy (SANTE) study 1 targeted the anterior nucleus of the thalamus and the NeuroPace study 2 evaluated responsive stimulation in different targets.
The hippocampus is a highly epileptogenic structure and can represent the main epileptogenic area in patients with mesial temporal sclerosis (MTS) or a main epilepticactivity-spreading relay in patients with temporal lobe epilepsy (TLE) with normal magnetic resonance imaging (MRI) findings or neocortical lesions. Microsurgical resection of the hippocampus has been performed extensively over the last decades, with high rates of seizure control. On the other hand, some patients with TLE might not be good candidates for temporal lobe resection due to memory concerns, poor seizure-onset localization/lateralization, associated disease, or personal preference. These patients are natural candidates for reversible neuromodulatory techniques, such as direct hippocampal stimulation.
Stimulation of the hippocampus for seizure control was initially reported almost simultaneously by Mexican and Belgium groups in the early 2000s. These open studies suggested that hippocampal stimulation was safe and effective in reducing seizures in patients with TLE; moreover, no new memory impairment occurred during hippocampal stimulation in these early studies. Our previous open-label study on hippocampal stimulation also suggested that unilateral or bilateral hippocampal stimulation was safe and effective in patients with TLE. These studies used a posterior approach for electrode insertion, since this method allows for sampling of larger portions of the hippocampus using a single electrode or "in tandem" electrodes. [3] [4] [5] [6] [7] [8] [9] Further evaluation of the results of hippocampal stimulation through adequately designed randomized clinical trials are needed. We designed a prospective, randomized, controlled, double-blind study to evaluate the efficacy of hippocampal deep brain stimulation (Hip-DBS) in patients with refractory TLE (rTLE).
Methods
Sixteen adult patients (11 women) were enrolled and submitted to Hip-DBS from September 2014 to August 2016. The study protocol was approved by the local ethics committee.
Patients were included if they had refractory epilepsy (to at least three medications in monotherapy or polytherapy) for at least 2 years, video-electroencephalography (EEG) recording, and MRI findings consistent with TLE; were not considered candidates for resective surgery (memory concerns or bilateral ictal onset); or declined resective surgery. They should be able to keep a seizure diary, have their medication regimen stable for at least 3 months before inclusion, and should not be taking more than four different seizure medications by the time of surgery. Seizure frequency must be at least four per month. Women must use adequate birth control methods. All patients signed an informed consent.
Patients were excluded if they had a clear history of pseudo-seizures, noncompliance, recent status epilepticus; had a progressive disease or severe systemic disease; had anatomic variations that could affect the implantation technique; had surgically resectable lesions (tumors, cavernoma, arteriovenous malformations, cortical dysplasia), had received experimental medications over the last 6 months; had already received deep brain stimulation; or could not comply with the visit's schedule.
Workup included medical history, interictal and ictal EEG, and high-resolution 1.5T MRI, with thin slices perpendicular to the hippocampal axis. Patients were randomized on a 1:1 proportion to an active (stimulation on) or to a control (no-stimulation) arm.
After enrollment, patients were followed for 3 months to define their preimplantation seizure frequency (M-3, M-2, M-1). After implantation, patients were allowed to recover for 1-month (M1), which was followed by a 1-month titration (or sham) period (M2). The 6-month blinded phase started immediately after M2 (Sz1, Sz2, Sz3, Sz4, Sz5, Sz6) ( Fig. 1) .
All patients had TLE and underwent unilateral or bilateral hippocampal lead implantation under general anesthesia using quadripolar Medtronic's 3391 electrode (Minneapolis, MN, U.S.A.); patients were implanted bilaterally when there was bilateral ictal onset or bilateral mesial temporal sclerosis (MTS). The electrodes were inserted using a posterior approach, using computed Figure 1 . Study design. Baseline seizure frequency was defined over a 3-month period before implantation. Patients were allowed to recover for 1 month, followed by a 1-month titration period. After full titration, a 6-month double-blind phase followed. Epilepsia ILAE
Key Points
• Hip-DBS was effective in reducing FAS and FIAS frequency in patients with refractory TLE who were not considered candidates for standard temporal lobe resection
• There was no short-term major morbidity or mortality • Short-term results were stable tomography (CT)/MRI fusion and intraoperative neuronavigation. The more anterior contact was targeted at the anterior head of the hippocampus; the more posterior one was located at the posterior body of the hippocampus. As detailed elsewhere, 10 recruiting responses were recorded on surface EEG over the targeted temporal lobe using low-frequency stimulation intraoperatively. A postoperative MRI confirmed the electrode's position in all patients. All patients received bipolar continuous nonresponsive stimulation. The anode was the more posterior contact, and the two more anterior contacts were used as cathodes. Stimulus duration was 300 ls and frequency was 130 Hz; final intensity was 2 V. Impedance tests were carried out on every visit. Medications were kept unaltered during the study period.
Patients kept a seizure diary during the study period. Seizures were counted using the diary and recorded monthly after implantation. Baseline seizure frequency was defined by the mean seizure frequency during the 3 months preceding implantation. After implantation, patients were allowed to recover for 1 month, followed by a 1-month intensity titration period, and a 6-month blinded phase. Patients were seen on a weekly basis during the titration phase and monthly during the blinded phase. During the titration phase, patients randomized to the control arm were submitted to impedance testing only (no stimulation); the patients randomized to the active arm received weekly 0.4 V stimulus intensity increments, reaching 2 V at the end of that phase. All programming was performed by a nontreating assistant. There was no sensation elicited by hippocampal stimulation, which allowed for both the patient and the treating physician to remain blinded. Patients were considered responders when they had at least 50% seizure frequency reduction during Hip-DBS. Patients in the control group also underwent implantation and received impedance tests only during the titration period. All control group patients received usual stimulation after the end of the blinded phase. They were otherwise treated in the same way as patients in the active group.
Patients and treating physicians were blinded during the recovery (1 month), titration (1 month), and follow-up (6 months) periods. Patients were considered seizure-free when they were free of seizures over the last 2 months of the blinded phase.
A database was created with the collected data and processed by means of descriptive statistics, with percentage, median, mean and standard deviation calculations. Analysis of variance (ANOVA, one-way) was used for comparison among groups, and chi-square or Fisher's exact test for comparison of proportions. All analyses were performed using SPSS (21.0) and p < 0.05 was set as the significance level.
Results
Age ranged from 14 to 55 years (mean 38.4 AE [standard deviation] 13.6 years); age at seizure onset ranged from 3 to 42 years (10.4 AE 9.9 years). All patients had focal impaired awareness seizures (FIAS, complex partial seizures), and 14 (87%) had focal aware seizures (FAS, simple partial seizures; 13 autonomic and one psychic). Seizure frequency ranged from 4 to 30 per month (12.5 AE 9.4 per month). MRI findings were normal in two patients, disclosed bilateral MTS in three, left MTS in five, and right MTS in six patients (Tables 1 and S1 ). Nine patients were receiving two different drugs, four were receiving three drugs, two were receiving four drugs, and one patient was receiving a single drug. An insertional effect could be noted in both the control and active patients. Although not statistically significant, patients who had a more pronounced insertional effect appeared to have a better outcome regarding seizure frequency. In the active group (n = 8), four patients became seizure-free; seven of eight were considered responders (>50% seizure frequency reduction) and one was a nonresponder. There was a statistically significant difference regarding FIAS frequency between the two groups from seizure 1 (Sz1) (first month of full stimulation; p < 0.001) to Sz6 (p < 0.001); the difference in seizure frequency between the control and active groups remained stable with longer follow-up during the blinded phase (Fig. 2) . There was a statistically significant difference between the control and active groups regarding FAS during the blinded phase (p < 0.006 at Sz1; p = 0.014 at Sz6), except for the Sz3 period (p = 0.249), although this significance was not as robust as for FIAS.
FAS appeared to be more refractory than FIAS to Hip-DBS in some patients. In the active group, one patient who became free of FIAS still presented FAS; an additional patient who attained 86% reduction in FIAS had only 45% reduction in FAS frequency.
Eleven patients with unilateral MTS were included in this study (six right MTS and five left MTS) who would be potentially good candidates for resective surgery. Among the patients with right MTS, one was denied resection for bilateral seizure-onset concerns, three refused any type of resective procedure, and two opted for trying a nonresective procedure first. Within the group with left MTS, one was denied resection for bilateral seizure onset concerns, two were not offered resective surgery for memory concerns, one refused any type of resective surgery, and one opted for trying a nonresective procedure first.
Two patients presented with local skin erosions and were treated with antibiotics. One patient received oral antibiotics for 10 days on an outpatient basis; the second patient received 10 days of oral antibiotics as an outpatient and was hospitalized for 2 weeks for treatment with intravenous antibiotics. Both erosions occurred at the cranial site of the Outcome regarding FAS and FIAS. There was a statistically significant difference from Sz1 onward (p < 0.001) in FIAS (right) during the blinded phase. Except for the Sz3 period, there was also a statistically significant difference in FAS (left) during the blinded phase. The statistical difference was more robust for FIAS. Vertical axis: Percentage of seizure frequency reduction. M1: recovery period; M2: titration period; Sz1: first month of the blinded phase; Sz2: second month of the blinded phase; Sz3: third month of the blinded phase; Sz4: fourth month of the blinded phase; Sz5: fifth month of the blinded phase; Sz6: sixth month of the blinded phase. CI, confidence interval. Epilepsia ILAE implant. There was no other morbidity or mortality in this series.
Discussion
Our data suggested that Hip-DBS is effective in significantly reducing the seizure frequency in the active group, as compared to the control group. Fifty percent of the patients in the active group became seizure-free. This seizure-free rate is similar to that reported in our open-label study (45%) 11 ; other studies reported a seizure-free rate ranging from 15-45%. 8, [12] [13] [14] [15] [16] [17] The present study is the largest prospective, controlled, double-blind study to evaluate the effects of Hip-DBS published to date.
An insertional effect was considered when there was seizure frequency reduction related to the insertion of the electrode itself (generator off). This insertional effect (likely related to intraoperative microlesion) could be seen in both active and control groups; this type of effect has already been noted in other series. 18 On the other hand, significant differences regarding seizure frequency were noted only after full generator activation (2 V) in the active group patients. There was a trend for those who would be good responders to disclose a more pronounced insertional effect, which might be related to a microlesion located in the most epileptogenic region in these patients.
The two previously published controlled studies on DBS for epilepsy were designed with only 3 months of a blinded phase; statistical significance was reached on the last blinded months, and the control and active arms seem to be getting further apart with time in these studies. This led us to include a larger 6-month blinded period. Although the differences found in the present study were significant from Sz1 onward, the more prolonged blinded phase was helpful in characterizing the timing, stability, and amplitude of this differentiation. A 2-month period before full stimulation was reached (1 month for surgical recovery and 1 month for titration) might also had help in diminishing the influence of the insertional effect influence in seizure count. Additional improvement over time was noticed in the longterm follow-up in many neuromodulation studies. In the present study, short-term (6 months) results remained stable from Sz1 onward; it is yet unclear if better results would be obtained after longer follow-up.
Although we included data on FAS, it is likely that due to the totally subjective nature of temporal lobe FAS, and the difficulty in documenting and counting the seizures, that such results would be much more unreliable than those regarding FIAS. On the other hand, the presence of residual FAS in patients free from FIAS might suggest that the stimulus amplitude selected in this study might be lower than was needed. Additional studies comparing different (higher) amplitude paradigms would be needed to further address this issue.
A larger number of patients would be needed to address how MRI findings affect Hip-DBS outcome. Some reports have suggested that patients with MTS would have a worse response to Hip-DBS. 8 Our previous open-label study was not able to show any differential outcome in patients with MTS or normal MRI 11 ; patients with MTS actually did better than those with normal MRI in the present study.
In this study, we used 3391 R electrodes, which were basically borrowed from obsessive compulsive disorder therapy. This electrode could cover a 2.5-cm span, including the hippocampal head and body and had only four contacts. An electrode more suitable for Hip-DBS should be developed, including a higher number of contacts and longer contact span. We used continuous stimulation, but it is reasonable to consider that if adequate sensing paradigms are developed, the system might evolve in the closed-loop system direction. If so, adequate electrodes that include both sensing and stimulating capabilities would also need to be developed.
Hip-DBS proved to be a safe and effective option in the treatment of patients with refractory TLE who are not candidates for standard temporal lobe resection. Improvement in hardware technology and stimulation paradigms might lead to even better results regarding seizure control.
